Accessibility Menu
Santhera Pharmaceuticals Ag logo

Santhera Pharmaceuticals Ag

(OTC) SPHDF

Current Price$23.25
Market Cap$344.91M
Since IPO (2009)-91%
5 Year-21%
1 Year+33%
1 Month+19%

Santhera Pharmaceuticals Ag Financials at a Glance

Market Cap

$344.91M

Revenue (TTM)

CHF 116.33M

Net Income (TTM)

-CHF 91.21M

EPS (TTM)

-$4.50

P/E Ratio

-5.17

Dividend

$0.00

Beta (Volatility)

-0.04 (Low)

Price

$23.25

Volume

3,200

Open

$23.25

Previous Close

$23.25

Daily Range

$23.25 - $23.25

52-Week Range

$12.28 - $23.25

Estimated Earnings Date

Sep 21, 2026

SPHDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Santhera Pharmaceuticals Ag

Industry

Biotechnology

Employees

93.6

CEO

Dario Eklund

Headquarters

Pratteln, 4133, CH

SPHDF Financials

Key Financial Metrics (TTM)

Gross Margin

19%

Operating Margin

-49%

Net Income Margin

-64%

Return on Equity

-742%

Return on Capital

-44%

Return on Assets

-33%

Earnings Yield

-19.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$344.91M

Shares Outstanding

14.83M

Volume

3.20K

Avg. Volume

162.656

Financials (TTM)

Gross Profit

CHF 14.47M

Operating Income

-CHF 37.83M

EBITDA

-CHF 32.14M

Operating Cash Flow

-CHF 34.78M

Capital Expenditure

-CHF 52.03K

Free Cash Flow

-CHF 34.83M

Cash & ST Invst.

CHF 22.45M

Total Debt

CHF 97.81M

Santhera Pharmaceuticals Ag Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CHF 53.20M

-46.5%

Gross Profit

CHF 22.93M

-76.6%

Gross Margin

43.11%

N/A

Market Cap

$344.91M

N/A

Market Cap/Employee

$4.42M

N/A

Employees

78

N/A

Net Income

-CHF 10.41M

-113.3%

EBITDA

CHF 480.23K

-99.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CHF 22.45M

-26.1%

Total Debt

CHF 97.81M

+353.9%

Accounts Receivable

CHF 26.05M

+5820.6%

Inventory

CHF 24.88M

+1273.8%

Long Term Debt

CHF 74.07M

+4037.0%

Short Term Debt

CHF 14.85M

-31.0%

Return on Assets

-33.25%

N/A

Return on Invested Capital

-44.02%

N/A

Free Cash Flow

-CHF 14.22M

-122.7%

Operating Cash Flow

-CHF 14.17M

-122.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNCFSilence Therapeutics plc
$2.21+0.00%
GNFTFGenfit S.A.
$9.98+0.00%
MLLCFMolecular Partners AG
$4.85+0.00%
IPHYFInnate Pharma S.A.
$1.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$185.00-0.04%
NOKNokia
$13.49-0.02%
AALAmerican Airlines Group
$15.99+0.04%
PFEPfizer
$25.21-0.03%

Questions About SPHDF

What is the current price of Santhera Pharmaceuticals Ag?

Santhera Pharmaceuticals Ag is trading at $23.25 per share.

What is the 52-week range for Santhera Pharmaceuticals Ag?

Over the past 52 weeks, Santhera Pharmaceuticals Ag has traded between $12.28 and $23.25.

How much debt does Santhera Pharmaceuticals Ag have?

As of the most recent reporting period, Santhera Pharmaceuticals Ag reported total debt of CHF 123.40M.

How much cash does Santhera Pharmaceuticals Ag have on hand?

Santhera Pharmaceuticals Ag reported CHF 28.32M in cash and cash equivalents in its most recent financial results.

What is Santhera Pharmaceuticals Ag’s dividend yield?

Santhera Pharmaceuticals Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.